BriaCell Therapeutics Corp.(BCTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BCTX BriaCell Therapeutics Corp.

Market Closed 06-12 16:00:00 EDT

2.77

+0.03

+1.09%

盘后2.78

+0.01+0.36%

18:52 EDT

High2.89	Low2.63	Vol192.40K
Open2.78	D1 Closing2.74	Amplitude9.49%
Mkt Cap24.10M	Tradable Cap21.77M	Total Shares8.70M
T/O526.92K	T/O Rate2.45%	Tradable Shares7.86M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BCTX","market":"US","secType":"STK","nameCN":"BriaCell Therapeutics Corp.","latestPrice":2.77,"timestamp":1781294400000,"preClose":2.74,"halted":0,"volume":192403,"hourTrading":{"tag":"盘后","latestPrice":2.78,"preClose":2.77,"latestTime":"18:52 EDT","volume":1596,"amount":4402.44,"timestamp":1781304773852,"change":0.01,"changeRate":0.00361,"amplitude":0.01083},"delay":0,"changeRate":0.010948905109488979,"floatShares":7859600,"shares":8699800,"eps":-9.659207,"marketStatus":"Market Closed","change":0.03,"latestTime":"06-12 16:00:00 EDT","open":2.78,"high":2.89,"low":2.63,"amount":526917.5109614,"amplitude":0.094891,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-9.659207,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1781510400000},"marketStatusCode":7,"adr":0,"listingDate":1614142800000,"exchange":"NASDAQ","adjPreClose":2.74,"preHourTrading":{"tag":"盘前","latestPrice":2.8644,"preClose":2.74,"latestTime":"08:33 EDT","volume":362,"amount":1037.1414754,"timestamp":1781267583633,"change":0.1244,"changeRate":0.045401,"amplitude":0.040146},"postHourTrading":{"tag":"盘后","latestPrice":2.78,"preClose":2.77,"latestTime":"18:52 EDT","volume":1596,"amount":4402.44,"timestamp":1781304773852,"change":0.01,"changeRate":0.00361,"amplitude":0.01083},"volumeRatio":0.765825,"impliedVol":0.6056,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/BCTX/tweets","defaultTab":"tweets","newsList":[{"id":"2642911418","title":"BriaCell Therapeutics Q3 EPS $(0.99) Up From $(16.40) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2642911418","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642911418?lang=en_us&edition=fundamental","pubTime":"2026-06-10 06:08","pubTimestamp":1781042925,"startTime":"0","endTime":"0","summary":"BriaCell Therapeutics (NASDAQ:BCTX) reported quarterly losses of $(0.99) per share. This is a 93.96 percent increase over losses of $(16.40) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/06/53105477/briacell-therapeutics-q3-eps-0-99-up-from-16-40-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BriaCell Therapeutics Q3 EPS $(0.99) Up From $(16.40) YoY","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640906961","title":"BriaCell Therapeutics Completes Equity Offering to Fund Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2640906961","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640906961?lang=en_us&edition=fundamental","pubTime":"2026-06-03 18:48","pubTimestamp":1780483689,"startTime":"0","endTime":"0","summary":"BriaCell Therapeutics ( ($TSE:BCT) ) just unveiled an update. On May 31, 2026, BriaCell Therapeutics entered into a placement agency agreement with...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/briacell-therapeutics-completes-equity-offering-to-fund-operations?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/briacell-therapeutics-completes-equity-offering-to-fund-operations?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4215","BK4588","BK4585","EQR","BCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640256179","title":"BriaCell Therapeutics Closes $4.7 Million Share Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2640256179","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640256179?lang=en_us&edition=fundamental","pubTime":"2026-06-03 04:24","pubTimestamp":1780431888,"startTime":"0","endTime":"0","summary":"BriaCell Therapeutics Corp  said Tuesday it has closed its best-efforts offering of roughly 1.45 million shares at $3.25 per share, for gross proceeds of about $4.7 million.Net proceeds will be used for working capital, general corporate purposes, as well as the advancement of business goals, the company said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640923783","title":"BriaCell Therapeutics Announces Closing of Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2640923783","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640923783?lang=en_us&edition=fundamental","pubTime":"2026-06-03 04:05","pubTimestamp":1780430700,"startTime":"0","endTime":"0","summary":"PHILADELPHIA & VANCOUVER, British Columbia, June  02, 2026  (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biot","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/02/3305594/0/en/BriaCell-Therapeutics-Announces-Closing-of-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640959383","title":"BriaCell Presents Positive Clinical Data at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640959383","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640959383?lang=en_us&edition=fundamental","pubTime":"2026-06-01 19:30","pubTimestamp":1780313400,"startTime":"0","endTime":"0","summary":"Final Bria-IMT Phase 2 data show 55% >1 year and 27% >2-year survival in heavily pre-treated metastatic breast cancer (MBC) patients treated with Bria-IMT regimen selected for Phase 3TWiST analysis, w","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304255/0/en/BriaCell-Presents-Positive-Clinical-Data-at-ASCO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4023","LU1815336091.USD","BK4080","BK4211","BK4195","BK4231","PFS","BK4086","BCTX","MBC","CPI","BL","ADC","LU0757428866.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640293125","title":"BriaCell Therapeutics Prices $4.7 Million Share Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2640293125","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640293125?lang=en_us&edition=fundamental","pubTime":"2026-06-01 15:59","pubTimestamp":1780300785,"startTime":"0","endTime":"0","summary":"BriaCell Therapeutics  said Sunday it priced a best-efforts offering of roughly 1.4 million shares at $3.25 each, raising gross proceeds of about $4.7 million.The offering is expected to close on Tuesday.The company said it plans to use the proceeds for working capital, general corporate purposes, and advancing its business objectives.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640818479","title":"BriaCell Therapeutics Announces Pricing of Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2640818479","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640818479?lang=en_us&edition=fundamental","pubTime":"2026-06-01 07:59","pubTimestamp":1780271940,"startTime":"0","endTime":"0","summary":"PHILADELPHIA and VANCOUVER, British Columbia, May  31, 2026  (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage bio","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/31/3303968/0/en/BriaCell-Therapeutics-Announces-Pricing-of-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638251974","title":"BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2638251974","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638251974?lang=en_us&edition=fundamental","pubTime":"2026-05-26 19:30","pubTimestamp":1779795000,"startTime":"0","endTime":"0","summary":"Independent DSMB has identified no safety concerns, to date, and recommends continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT plus immune check point inhibitorSixth consecutive positive DSM","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/26/3300964/0/en/BriaCell-Receives-Positive-Recommendation-from-Data-Safety-Monitoring-Board-DSMB-for-Phase-3-Study-in-Metastatic-Breast-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CPI","BCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637631319","title":"BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2637631319","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637631319?lang=en_us&edition=fundamental","pubTime":"2026-05-22 19:30","pubTimestamp":1779449400,"startTime":"0","endTime":"0","summary":"Final Phase 2 Bria-IMT median overall survival (OS) is 16.6 months (with Phase 3 formulation) Positive Quality of Life (QOL) data from the ongoing Phase 3 study in heavily pre-treated metastatic breas","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/22/3300068/0/en/BriaCell-Presentations-Highlight-Positive-Clinical-Data-for-Bria-IMT-at-ASCO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","BK4231","MBC","CPI","BK4124","BK4080","PFS","BK4086","CPS","BK4211","DTH","BK4195","BCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635089191","title":"BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™","url":"https://stock-news.laohu8.com/highlight/detail?id=2635089191","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635089191?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:30","pubTimestamp":1778844600,"startTime":"0","endTime":"0","summary":"BriaCell expands push in women’s health, building on Phase 2 success in advanced metastatic breast cancerBria-OVA+, BriaCell’s next generation personalized immunotherapy candidate for ovarian cancer, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/15/3295754/0/en/BriaCell-Expands-Pipeline-to-Include-an-Ovarian-Cancer-Immunotherapy-Candidate-Bria-OVA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCTX","ATCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635714106","title":"BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2635714106","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635714106?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:30","pubTimestamp":1778758200,"startTime":"0","endTime":"0","summary":"Bria-PROS+ is BriaCell’s next generation personalized off-the-shelf immunotherapy for prostate cancerImmune stimulating components of Bria-PROS+ enhance anti-tumor responsesBriaCell has completed manu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3294795/0/en/BriaCell-Completes-Manufacturing-of-Clinical-Supplies-of-Bria-PROS-for-Prostate-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","BK4139","BCTX","PROS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635789046","title":"BriaCell Adds Penn Medicine’s Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2635789046","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635789046?lang=en_us&edition=fundamental","pubTime":"2026-05-13 19:30","pubTimestamp":1778671800,"startTime":"0","endTime":"0","summary":"Other recently activated sites include Indiana University Melvin and Bren Simon Comprehensive Cancer Center, University of Virginia (UVA) Comprehensive Cancer Center, Baptist Health South Florida, and","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/13/3293887/0/en/BriaCell-Adds-Penn-Medicine-s-Abramson-Cancer-Center-as-Clinical-Site-in-Pivotal-Phase-3-Breast-Cancer-Study.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634216305","title":"BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2634216305","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634216305?lang=en_us&edition=fundamental","pubTime":"2026-05-12 19:30","pubTimestamp":1778585400,"startTime":"0","endTime":"0","summary":"Over 315 patients screened and over 230 patients enrolled in BriaCell’s pivotal Phase 3 Bria-ABC study of Bria-IMT plus immune checkpoint inhibitor in metastatic breast cancerEnrollment momentum conti","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/12/3292721/0/en/BriaCell-Phase-3-Bria-IMT-Study-Enrollment-Surpasses-230-Patients.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633809051","title":"BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2633809051","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2633809051?lang=en_us&edition=fundamental","pubTime":"2026-05-06 19:30","pubTimestamp":1778067000,"startTime":"0","endTime":"0","summary":"FDA clearance of Investigational New Drug (IND) application opens path to commence Phase 1/2a clinical study for Bria-BRES+ in metastatic breast cancerBria-BRES+ is BriaCell’s next generation personal","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/06/3288700/0/en/BriaCell-Receives-FDA-Clearance-to-Initiate-Bria-BRES-Clinical-Study-in-Breast-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTX","BRES","LABU","MBC","BK4086","BK4585","BK4139","BK4588","IND"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630395699","title":"BriaCell Announces Six Clinical Data Presentations at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2630395699","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630395699?lang=en_us&edition=fundamental","pubTime":"2026-04-27 19:30","pubTimestamp":1777289400,"startTime":"0","endTime":"0","summary":"Final randomized Phase 2 Bria-IMT survival and quality of life data to be presentedBiomarker analyses from the ongoing Phase 3 study evaluating predictors of response  PHILADELPHIA and VANCOUVER, Brit","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/27/3281510/0/en/BriaCell-Announces-Six-Clinical-Data-Presentations-at-ASCO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629036113","title":"BriaCell presents anti-cancer activity of Bria-OTS","url":"https://stock-news.laohu8.com/highlight/detail?id=2629036113","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629036113?lang=en_us&edition=fundamental","pubTime":"2026-04-21 19:54","pubTimestamp":1776772463,"startTime":"0","endTime":"0","summary":"BriaCell (BCTX) Therapeutics is presenting “positive” data from its preclinical Bria-OTS+ platform at the 2026 American Association for Cancer Rese...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/briacell-presents-anti-cancer-activity-of-bria-ots-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/briacell-presents-anti-cancer-activity-of-bria-ots-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628747963","title":"BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2628747963","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628747963?lang=en_us&edition=fundamental","pubTime":"2026-04-20 19:30","pubTimestamp":1776684600,"startTime":"0","endTime":"0","summary":"Phase 3 clinical data in heavily pretreated metastatic breast cancer patients with prior failed ADC, CPI, and CDK4/6 inhibitor treatments shows quality of life (QOL) largely preservedIdentification of","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/04/20/3276889/0/en/BriaCell-Presents-Positive-Phase-3-Quality-of-Life-and-Phase-2-Biomarker-Data-at-the-2026-AACR-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ADC","BK4080","BCTX","BK4231","BK4139","BK4086","MBC","CPI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624332554","title":"BriaCell Therapeutics Reports Rising Losses and Funding Pressure","url":"https://stock-news.laohu8.com/highlight/detail?id=2624332554","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624332554?lang=en_us&edition=fundamental","pubTime":"2026-04-01 07:35","pubTimestamp":1775000141,"startTime":"0","endTime":"0","summary":"An announcement from BriaCell Therapeutics ( ($TSE:BCT) ) is now available. On March 31, 2026, BriaPro Therapeutics filed unaudited condensed inter...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/briacell-therapeutics-reports-rising-losses-and-funding-pressure?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/briacell-therapeutics-reports-rising-losses-and-funding-pressure?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624537178","title":"BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License","url":"https://stock-news.laohu8.com/highlight/detail?id=2624537178","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624537178?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:05","pubTimestamp":1774987500,"startTime":"0","endTime":"0","summary":"PHILADELPHIA and VANCOUVER, British Columbia, March  31, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“BriaCell”), a clinical-stage biotechnolog","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/31/3266014/0/en/BriaCell-and-BriaPro-Announce-Closing-of-Asset-Purchase-Transaction-for-Exclusive-Soluble-CD80-License.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620587842","title":"BriaCell to present four posters at the 2026 AACR","url":"https://stock-news.laohu8.com/highlight/detail?id=2620587842","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620587842?lang=en_us&edition=fundamental","pubTime":"2026-03-18 19:42","pubTimestamp":1773834175,"startTime":"0","endTime":"0","summary":"BriaCell (BCTX) Therapeutics announces that it will present four posters at the 2026 American Association for Cancer Research, or AACR, Annual Meet...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/briacell-to-present-four-posters-at-the-2026-aacr-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/briacell-to-present-four-posters-at-the-2026-aacr-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCTX"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://briacell.com","stockEarnings":[{"period":"1week","weight":-0.1006},{"period":"1month","weight":-0.3373},{"period":"3month","weight":-0.3436},{"period":"6month","weight":-0.7096},{"period":"1year","weight":-0.9215},{"period":"ytd","weight":-0.6104}],"compareEarnings":[{"period":"1week","weight":0.0057},{"period":"1month","weight":-0.0008},{"period":"3month","weight":0.12},{"period":"6month","weight":0.088},{"period":"1year","weight":0.2286},{"period":"ytd","weight":0.0877}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.124732},{"month":2,"riseRate":0.2,"avgChangeRate":-0.077389},{"month":3,"riseRate":0.666667,"avgChangeRate":0.07242},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.063453},{"month":5,"riseRate":0,"avgChangeRate":-0.196006},{"month":6,"riseRate":0.5,"avgChangeRate":0.025749},{"month":7,"riseRate":0.4,"avgChangeRate":-0.192928},{"month":8,"riseRate":1,"avgChangeRate":0.139099},{"month":9,"riseRate":0.6,"avgChangeRate":0.155119},{"month":10,"riseRate":0,"avgChangeRate":-0.140813},{"month":11,"riseRate":0.6,"avgChangeRate":0.110284},{"month":12,"riseRate":0.2,"avgChangeRate":-0.186609}],"exchange":"NASDAQ","name":"BriaCell Therapeutics Corp.","nameEN":"BriaCell Therapeutics Corp."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BriaCell Therapeutics Corp.(BCTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BriaCell Therapeutics Corp.(BCTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BriaCell Therapeutics Corp.,BCTX,BriaCell Therapeutics Corp.股票,BriaCell Therapeutics Corp.股票老虎,BriaCell Therapeutics Corp.股票老虎国际,BriaCell Therapeutics Corp.行情,BriaCell Therapeutics Corp.股票行情,BriaCell Therapeutics Corp.股价,BriaCell Therapeutics Corp.股市,BriaCell Therapeutics Corp.股票价格,BriaCell Therapeutics Corp.股票交易,BriaCell Therapeutics Corp.股票购买,BriaCell Therapeutics Corp.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BriaCell Therapeutics Corp.(BCTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BriaCell Therapeutics Corp.(BCTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}